Related companies

Description

Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. Alexza’s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. The Company has one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. Its product candidates not in active development are AZ-007 (Staccato zaleplon), AZ-104 (Staccato loxapine, low-dose) AZ-003 (Staccato fentanyl) and AZ-003 (Staccato fentanyl). The Company has retained all rights to the Staccato system and to its product candidates other than ADASUVE and AZ-104 (Staccato loxapine, low-dose).